LB Pharmaceuticals Inc Dossier
|
SectorHealth Care IndustryPharmaceuticals Beta (adjusted)1.16 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $37.28Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $1.2B Enterprise Value $910.9M Shares Outstanding 29.4M diluted Next Earnings Date15 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary LB Pharmaceuticals is a late-stage clinical biopharmaceutical company uniquely positioned to disrupt the U.S. neuropsychiatry market with LB-102, a novel methylated derivative of the widely used European antipsychotic amisulpride. By optimizing blood-brain barrier penetration, LB-102 enables once-daily oral dosing at lower concentrations, aiming to deliver amisulpride's established efficacy with a superior safety and tolerability profile. Backed by a robust cash position of $365.6 million as of March 31, 2026, which funds operations into Q2 2029, the company is well-capitalized to execute multiple high-value clinical milestones, including the Phase 3 NOVA-2 trial in schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar depression. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$37.00 Mean target$51.50 High · most bullish analyst$78.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $15.0015% The Phase 3 NOVA-2 trial fails to meet its primary endpoint of statistically significant PANSS reduction compared to placebo, or reveals unexpected safety concerns (such as severe QT prolongation or prolactin-related toxicities). This halts the development of LB-102 and severely impairs the company's valuation, leaving it dependent on its remaining cash reserves. Base CaseCentral scenario $45.8860% LB-102 successfully meets its primary endpoints in the Phase 3 NOVA-2 trial with efficacy comparable to or slightly better than standard of care, accompanied by a favorable safety profile. The drug secures FDA approval for schizophrenia, and the Phase 2 trials in bipolar depression and adjunctive MDD progress on track, establishing a solid foundation for commercial launch. Bull CaseUpside scenario $81.9025% LB-102 demonstrates superior efficacy and class-leading tolerability in the Phase 3 NOVA-2 trial, showing significant cognitive benefits and minimal weight gain or extrapyramidal symptoms. This leads to rapid FDA approval in schizophrenia and successful expansion into bipolar depression and adjunctive MDD, unlocking a multi-billion dollar blockbuster franchise. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |